Arrowstreet Capital’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Arrowstreet Capital’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-75,811	Closed	-$834K	–	1627
2016 Q1	$834K	Sell	75,811 -25,050	-25%	-$223K	﹤0.01%	1010
2015 Q4	$928K	Buy	+100,861	New	+$844K	﹤0.01%	1006
2015 Q3	–	Sell	-151,048	Closed	-$1.48M	–	1588
2015 Q2	$1.48M	Buy	151,048 +44,443	+42%	+$405K	0.01%	709
2015 Q1	$945K	Buy	106,605 +69,542	+188%	+$554K	0.01%	727
2014 Q4	$325K	Buy	+37,063	New	+$300K	﹤0.01%	1112

Other funds holding SCLN

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital's SCLN Position: Q2 2016 in Review

Arrowstreet Capital sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2016, closing a stake of 75,811 shares — an estimated $834K sold.

Arrowstreet Capital first reported a position in SCLN in Q4 2014 and held it in 5 quarters. The position peaked at $1.48M in Q2 2015. 151 funds tracked by Wall St. Rank hold SCLN as of Q2 2016.

Arrowstreet Capital reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
Arrowstreet Capital sold 75,811 Sciclone Pharmaceuticals Inc shares in Q2 2016, an estimated $834K.
Arrowstreet Capital first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and held it in 5 quarters.
Arrowstreet Capital's Sciclone Pharmaceuticals Inc position peaked at $1.48M in Q2 2015.
151 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2016.

Based on Arrowstreet Capital's 13F filing for Q2 2016, filed 15 Aug 2016.